• SAR131675: A Mechanistic Assay Guide

  2026-08-31

  Explore SAR131675 as a selective ATP-competitive VEGFR-3 inhibitor through an attribution-first framework. This article connects kinase pharmacology, lymphangiogenesis assays, and nicotine-associated kidney disease research while clearly separating evidence from hypothesis.

• Morin Workflows for Stress and Energy Assays

  2026-08-30

  Morin combines flavonoid bioactivity with fluorescent metal-chelation, enabling complementary cell, mitochondrial, enzyme, and aluminum-detection workflows. This guide translates a clinically important neuroleptic malignant syndrome case into practical assay-design lessons without overstating Morin as a treatment or validated disease model.

• Enzyme-Induced Hypoxia Drives Urothelial Inflammation

  2026-08-29

  The reference study shows that brief enzyme-induced hypoxia can stabilize HIF-1α without activating the NLRP3 inflammasome, whereas longer exposure increases intracellular caspase-1 activity in urothelial cells. Antioxidant and TXNIP-inhibitory interventions implicate a ROS/TXNIP/NLRP3 pathway and provide a temporal framework for modeling bladder outlet obstruction-associated inflammation.

• Bufalin: From Steroid Scaffold to Target Validation

  2026-08-28

  Bufalin is a cardiotonic steroid with apoptosis-inducing, differentiation, and protein-degradation activities. This article presents an assay-centered framework for connecting Bufalin target engagement to mechanism in triple-negative breast cancer and hepatocellular carcinoma research.

• Bortezomib (PS-341) for Proteostasis Assays

  2026-08-28

  Bortezomib (PS-341) provides a reversible 20S proteasome perturbation for connecting proteostasis, cell death, and disease-model phenotypes. This guide translates its use into practical apoptosis, cancer, and TDP-43-related assay workflows while distinguishing established evidence from exploratory applications.

• 2-NBDG Glucose Uptake Assay Kit: Flux Context

  2026-08-28

  The 2-NBDG Glucose Uptake Assay Kit enables non-radioactive, single-cell analysis of glucose transport. This guide shows how to interpret uptake alongside ferroptosis and lipid-metabolism findings in sorafenib-resistant hepatocellular carcinoma without overstating what fluorescence alone can prove.

• GS-441524 Prodrug Pathways in Translational Research

  2026-08-27

  GS-441524 is more than a reference nucleoside: its translational value depends on activation, matrix-specific conversion, exposure, and analytical resolution. This article interprets recent LC–MS/MS evidence on GS-441524 prodrug pathways and translates it into practical guidance for antiviral, pharmacokinetic, and prodrug-development teams.

• Hyperoside, DHX9, and R-Loops in URSA

  2026-08-26

  This study identifies DHX9-mediated R-loop resolution as a mechanistic link between hyperoside treatment, reduced endometrial stromal cell senescence, and improved decidualization in unexplained recurrent spontaneous abortion. Its integrated human, mouse, and cellular design provides a useful framework for connecting genome-stability defects with reproductive outcomes while clarifying the limits of preclinical translation.

• CP-673451 in Cell Assay Workflows

  2026-08-26

  This scenario-driven guide explains how CP-673451 (SKU B2173) can improve interpretation of PDGFR-dependent viability, proliferation, cytotoxicity, and angiogenesis experiments. It combines product specifications with glioma literature to support solvent control, concentration selection, orthogonal validation, and practical vendor evaluation.

• Multi-Omics Maps ARID1A-Linked Melanoma Resistance

  2026-08-26

  The reference study integrates early signaling, molecular profiling, and network analysis to define how ARID1A loss rewires melanoma responses to BRAF/MAPK inhibition. Its identification of PRKD1, JUN, and NCK1 as resistance-associated nodes provides a framework for connecting adaptive signaling, immune visibility, and extracellular-matrix remodeling.

• EdU Flow Cytometry Assay Kits (Cy5) in Cancer Research

  2026-08-25

  Metabolic interventions can suppress tumor growth while simultaneously creating immune-evasion pressure. This thought-leadership analysis explains how EdU Flow Cytometry Assay Kits (Cy5) can turn that biological tension into a measurable S-phase endpoint for translational cancer research, using findings on serine/glycine restriction and PD-L1 lactylation as a strategic case study.

• VE-822 ATR Inhibitor: PDAC Research Workflow

  2026-08-24

  VE-822 is a potent ATR inhibitor for dissecting replication-stress signaling and testing combination strategies with gemcitabine or radiation. This practical guide connects DNA damage response inhibition with PDAC assay design, iPSC-informed model selection, dosing controls, and troubleshooting.

• Morin and the AMPD2 Energy Rescue Paradigm

  2026-08-24

  A translational perspective on how Morin connects AMPD2 activity, purine nucleotide cycling, mitochondrial dysfunction, and podocyte injury—while defining practical strategies for mechanism-first validation.

• SAG Protects Frataxin-Deficient Astrocytes

  2026-08-23

  Vicente-Acosta et al. showed that frataxin depletion drives mitochondrial dysfunction, reactive astrocyte features, inflammatory signaling, and neuron-toxic secreted effects in cultured human astrocytes. Chronic Smoothened receptor agonist treatment largely prevented these changes, identifying Hedgehog pathway activation as a potential strategy for modifying astrocyte-mediated neurodegeneration in Friedreich’s ataxia.

• Morin and the New Logic of Podocyte Energy Rescue

  2026-08-22

  Morin is emerging as more than a broadly active flavonoid: a mechanistically informative tool for connecting purine nucleotide cycling, mitochondrial energy failure, and podocyte injury. This thought-leadership perspective translates recent AMPD2 findings into practical guidance for disease-model design, compound handling, assay strategy, and translational decision-making.

8632 records 1/576 page Next 12345 下5页 Last page